TenthGate International

TenthGate International is a clinical-stage biopharmaceutical company based in Zug, Switzerland, focused on the development of targeted cancer immunotherapies. The company's primary asset is TG01, a polyvalent RAS mutant peptide vaccine that targets the most common RAS mutations found in solid tumors, including pancreatic, colorectal, and lung cancers. TenthGate acquired the global rights to the TG01 program from Targovax (now Circio) and is advancing it through Phase 2 clinical trials. By combining TG01 with standard-of-care treatments and other immunotherapies, the company seeks to improve outcomes for patients with difficult-to-treat RAS-mutated malignancies. The company operates with a lean, asset-centric model to efficiently progress its clinical pipeline.